Nucleo forte side effects series#
Gallbladder stone dissolution may take several months of therapy and complete dissolution may not occur reocurrence of stones may happen within 5 years in up to 50% of patients receiving therapyĪvailable published data on use of ursodiol in pregnant women derived from randomized controlled trials, observational studies, and case series collected over several decades have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes most reported exposures to ursodiol occurred in second and third trimester of pregnancy Animal data Patients with variceal bleeding, hepatic encephalopathy, ascites or in need of an urgent liver transplant, should receive appropriate specific treatment Liver function tests (gamma-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored q3months x3 months after start of therapy, and q6months thereafter consider treatment discontinuation if parameters increase to a level considered clinically significant in patients with history of stable liver function test levels In nonvisualizing gallbladders use caution and discontinue therapy if gallbladder nonvisualization occurs during treatment Only use in radiolucent, non calcified, high cholesterol content gallstone Patients requiring cholecystectomy Cautions Known hepatocyte or bile ductal abnormalities, inflammatory bowel diseaseĬalcified gallstones, bile acid allergy, chronic hepatic disease Monitor Closely (1)sodium citrate/citric acid decreases effects of ursodiol by pharmacodynamic antagonism. Monitor Closely (1)sodium bicarbonate decreases effects of ursodiol by pharmacodynamic antagonism. Minor (1)mestranol decreases effects of ursodiol by pharmacodynamic antagonism. Monitor Closely (1)ethinylestradiol decreases effects of ursodiol by pharmacodynamic antagonism. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates. Monitor Closely (1)eluxadoline increases levels of ursodiol by decreasing metabolism. Monitor Closely (1)crofelemer increases levels of ursodiol by Other (see comment). Minor (1)colestipol decreases effects of ursodiol by pharmacodynamic antagonism. Minor (1)colesevelam decreases effects of ursodiol by pharmacodynamic antagonism. Minor (1)cholestyramine decreases effects of ursodiol by pharmacodynamic antagonism. Monitor Closely (1)calcium carbonate decreases effects of ursodiol by pharmacodynamic antagonism. Monitor Closely (1)aluminum hydroxide decreases effects of ursodiol by pharmacodynamic antagonism. Mestranol decreases effects of ursodiol by pharmacodynamic antagonism. Minor/Significance Unknown.Ĭolestipol decreases effects of ursodiol by pharmacodynamic antagonism.
Minor/Significance Unknown.Ĭolesevelam decreases effects of ursodiol by pharmacodynamic antagonism.
Use Caution/Monitor.Ĭholestyramine decreases effects of ursodiol by pharmacodynamic antagonism. Sodium citrate/citric acid decreases effects of ursodiol by pharmacodynamic antagonism. Sodium bicarbonate decreases effects of ursodiol by pharmacodynamic antagonism.
Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.Įthinylestradiol decreases effects of ursodiol by pharmacodynamic antagonism. Use Caution/Monitor.Ĭomment: Crofelemer has the potential to inhibit transporters MRP2 and OATP1A2 at concentrations expected in the gut unlikely to inhibit systemically because minimally absorbed.Įluxadoline increases levels of ursodiol by decreasing metabolism. Use Caution/Monitor.Ĭrofelemer increases levels of ursodiol by Other (see comment). Use Caution/Monitor.Ĭalcium carbonate decreases effects of ursodiol by pharmacodynamic antagonism. Aluminum hydroxide decreases effects of ursodiol by pharmacodynamic antagonism.
0 kommentar(er)
